Brief: Dice Therapeutics Announces Completion Of Enrollment In Phase 1 Clinical Trial Of Lead Oral IL-17 Antagonist, DC-806, For The Treatment Of Psoriasis

Dice Therapeutics

21/07/2022 21:24

July 21 (Reuters) - Dice Therapeutics Inc  DICE.O :
    * DICE THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN
PHASE 1
CLINICAL TRIAL OF LEAD ORAL IL-17 ANTAGONIST, DC-806, FOR THE
TREATMENT OF PSORIASIS
    * DICE THERAPEUTICS INC - TOPLINE PROOF-OF-CONCEPT DATA IN
HEALTHY
VOLUNTEERS AND PSORIASIS PATIENTS EXPECTED IN 2H 2022

Source text for Eikon:  ID:nGNX4xV8Tz 
Further company coverage:  DICE.O 

 ((Reuters.Briefs@thomsonreuters.com;))